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Abstract  More  than  90%  of  cases  of  hepatocellular  carcinoma  occur  on  the  background  of
chronic liver  disease.  Its  diagnosis  should  therefore  be  based  on  six-month  ultrasound  screening,
which should  be  started  in  these  patients.  The  positive  diagnosis  of  hepatocellular  carcinoma  is
based on  its  vascularization  examined  on  dynamic  CT  or  MRI  images  after  contrast  enhancement.
Arterial hypervascularization  followed  by  a  washout  from  the  lesion  in  the  portal  and/or  late
phases on  a  background  of  cirrhosis  provides  a  positive  diagnosis  of  HCC  without  histology  for
nodules over  a  centimeter  in  size  (international  guidelines).  Any  other  appearances  require
needle biopsy  of  the  nodule  and  extra-nodular  area  to  conﬁrm  the  diagnosis.  The  local  staging
assessment  predominantly  involving  portal  invasion  and  the  general  patient  assessment  should
be combined  with  assessment  of  the  underlying  liver  disease  to  guide  the  treatment  decision.
The information  obtained  should  be  contained  in  as  standardized  a  report  as  possible  with  all
of the  information  required  for  patient  management.
© 2014  Éditions  franc¸aises  de  radiologie.  Published  by  Elsevier  Masson  SAS.  All  rights  reserved.
Hepatocellular  carcinoma  has  two  speciﬁc  diagnostic  features.
Firstly,  it  occurs  on  a  background  of  chronic  underlying  liver  disease  in  more  than  90%
of  cases  [1—3]  and  the  existence  of  a  predisposing  background  has  led  to  the  introduction
of  six-monthly  screening  in  at  risk  patients  in  order  to  identify  hepatocellular  carcinomas
early  when  it  is  at  a  stage  which  allows  curative  therapy  to  be  offered  [4].  Despite  the  poor
prognosis  of  HCC,  however,  screening  is  not  widely  used.  It  is  carried  out  in  approximately
25%  of  patients  in  France  [5].The  second  speciﬁc  feature  of  the  diagnosis  of  hepatocellular  carcinoma  is  that  an
unequivocal  diagnosis  can  be  made  on  imaging  criteria  without  the  need  for  histology  [6],
hence  the  need  for  a  thorough  method  and  careful  analysis  of  the  appearances  of  lesions
which  may  to  represent  hepatocellular  carcinoma.
∗ Corresponding author.
E-mail address: victoirecartier@hotmail.com (V. Cartier).
http://dx.doi.org/10.1016/j.diii.2014.06.004
2211-5684/© 2014 Éditions franc¸aises de radiologie. Published by Elsevier Masson SAS. All rights reserved.
7l
a
m
a
a
a
o
i
o
t
I
U
U
l
s
r
n
C
n
g
r
a
d
n
C
L
c
t
p
i
p
a
a
A
p
s
1
m
M
M
t
i
t
T
n
b
o
h
t
l
a
I
c
T
T
g
p
U
n
l
w
s
o
[
n
s
c
o
l
i
t
a
o
r
i
H
o
A
A
A
H
o
d
t
i
a
o
•
•
unevenly  in  the  arterial  phase  [17];10  
As  applies  to  any  cancer,  the  diagnosis  of  hepatocellu-
ar  carcinoma  should  be  combined  with  a  local,  regional
nd  systemic  staging  assessment.  Beyond  the  staging  assess-
ent,  however,  the  underlying  liver  disease  is  a  fundamental
spect  of  patient  management.  Hepatocellular  impairment
nd  portal  hypertension  associated  with  the  liver  disease
re  factors,  which  are  added  to  the  staging  assessment  in
rder  to  choose  appropriate  treatment.  This  information  is
ncluded  in  the  BCLC  classiﬁcation,  which  is  currently  the
nly  classiﬁcation  that  is  currently  recognized  by  interna-
ional  guidelines  [3,6].
maging techniques
ltrasound
ltrasound  is  the  investigation,  which  should  identify  the
argest  number  of  hepatocellular  carcinomas,  as  it  is  the
creening  method  used  for  six-monthly  monitoring  of  cir-
hosis.  It  should,  therefore,  look  for  development  of  new
odules  or  changes  in  the  appearance  of  known  nodules.
ontrast-enhanced  ultrasound  is  no  longer  recognized  as  a
oninvasive  part  of  the  diagnosis  in  the  recent  international
uidelines  [6].  It  is  still,  however,  useful  in  monitoring  cir-
hosis  in  order  to  distinguish  a  regenerative  nodule  from
 small  hepatocellular  carcinoma  or  in  a  diagnostic  nee-
le  biopsy  or  percutaneous  treatment  to  clearly  identify  the
odule  to  be  biopsied  or  treated.
omputed tomography
iver  investigations  in  the  diagnosis  of  hepatocellular  car-
inoma  should  include  four  phases:  one  phase  without  and
hree  phases  with  contrast  enhancement:  one  in  the  arterial
hase  (30  to  35  seconds  after  beginning  the  injection),  one
n  the  portal  phase  (75  to  90  seconds)  and  one  in  the  late
hase  (3  minutes).  The  portal  phase  should  cover  the  entire
bdominal  and  pelvic  cavities  in  order  to  provide  a  staging
ssessment  and  investigate  for  signs  of  portal  hypertension.
 chest  investigation  should  be  carried  out  in  the  arterial
hase.  The  iodine  concentration  in  the  contrast  medium
hould  be  350  g/L,  with  an  injection  volume  of  between
.5  and  2  mL/kg  (in  practice  between  120  and  150  mL).  The
inimum  injection  ﬂow  rate  should  be  3  mL/s.
agnetic resonance imaging
RI  is  still  the  best  investigation  to  detect  and  characterize
he  different  nodules,  which  develop  in  cirrhosis  [7].
The  investigation  involves  a  rapid  spin  echo  T2  weighted
mage  with  fat  saturation  (fat  saturation  increases  the  con-
rast  of  the  lesion),  an  both  in  phase  and  out  of  phase
1  echo  gradient  image  to  investigate  for  a  fatty  compo-
ent  in  the  tumor  and  a  diffusion-weighted  image  with  a
 value  of  approximately  600  mm/s2 to  improve  detection
f  small  lesions  and  help  in  their  characterization,  unen-
anced  T1  weighted  image  with  fat  saturation  without  and
hen  after  contrast  enhancement  in  the  arterial,  portal  and
ate  phases.
Ideally,  if  large  volume  ascites  is  present,  this  should  be
spirated  in  advance  in  order  to  reduce  movement  artefacts.
•V.  Cartier,  C.  Aubé
maging appearances of hepatocellular
arcinoma
ypical appearance
he  most  common  form  of  hepatocellular  carcinoma  is  sin-
le  or  a  small  number  (3  to  4)  of  nodular  lesions.  A  capsule  is
resent  in  75%  of  cases  of  HCC  over  2  centimeters  in  size  [8].
nenhanced,  the  nodule  has  variable  echogenicity  (small
odules  are  slightly  more  often  hypoechogenic)  but  is  more
ikely  to  be  slightly  hypodense  on  CT,  hypointense  on  T1
eighted  MRI  and  hyperintense  on  T2  weighted  MRI  [9].
A  hyperintensity  on  diffusion-weighted  imaging  is  highly
uggestive  of  hepatocellular  carcinoma,  although  absence
f  a  diffusion-weighted  hyperintensity  in  no  way  excludes  it
10].
The  characteristic  appearance  is  vascularization  of  the
odule  due  to  arterial  neoangiogenesis,  which  progressively
ubstitutes  an  arterial  vascularization  for  the  portal  vas-
ularization  of  the  regenerative  nodule.  The  typical  form
f  hepatocellular  carcinoma  therefore  displays  hypervascu-
arisation  in  the  arterial  phase  followed  by  a hypodensity
n  the  portal  and/or  late  phase.  This  hypodensity  deﬁnes
he  washout  from  the  lesion  (Fig.  1).  Washout  is  deﬁned
s  a  hypodensity  compared  to  the  neighboring  parenchyma
ccurring  in  the  portal  and/or  late  phase  and  following  arte-
ial  hypervascularisation.  This  is  an  important  deﬁnition,  as
t  is  one  of  the  key  factors  in  the  noninvasive  diagnosis  of
CC  as  they  appear  in  the  international  guidelines  [6,11].
This  typical  appearance  is  increasingly  common  in  lesions
ver  2  centimeters  in  size.
typical appearances
typical  tumors
typical  numbers,  shapes  and  enhancement  are  seen  and  the
CC  may  be  multinodular  when  ﬁrst  found.  It  may  be  hypo-
r  isodense  in  the  arterial  or  portal  phases  and  not  therefore
isplay  any  characteristic  enhancement.  In  addition,  inﬁl-
rative  forms  are  seen  which  are  often  poorly  demarcated,
n  which  case  they  are  often  poorly  hypervascularized  in  the
rterial  phase.  These  atypical  tumors  account  for  15  to  20%
f  the  hepatocellular  carcinomas:
small  hepatocellular  carcinomas  (<  2  cm)  do  not  display
the  typical  appearances  in  20  to  60%  of  cases  depending  on
the  technique  used  [12—14]. Arterial  hypervascularization
and  washout  from  the  lesion  are  less  common  when  it  is
small  and  if  it  is  well  differentiated  [15].  The  histological
concept  of  the  early  HCC  is  often  a  lesion  between  10  and
15  mm  in  diameter  with  no  clearly  demarcated  outline
and  very  modest  arterial  vascularization  with  no  arterial
washout  (Fig.  2)  [16];
HCC occurring  in  steatotic  liver  disease  has  a  few  spe-
ciﬁc  features.  It  often  appears  as  a  large  heterogeneous
lesion  containing  areas  of  clearly  demarcated  necrosis
with  regular  outlines.  It  may  be  encapsulated  and  enhanceHCC  is  rare  in  a  healthy  liver  (incidence  <  10%)  and  in  20%
of  cases  is  associated  with  hepatitis  B  virus  infection,  as
the  virus  has  a  direct  carcinogenic  effect.  It  may,  however,
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Figure 1. Typical hepatocellular carcinoma in cirrhosis. Magnetic resonance imaging. T1 weighted images with fat saturation without (a)
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images (f).
develop  in  a  patient  with  no  known  cause  of  chronic  liver
disease  and  normal  liver  histology.  The  diagnosis  is  made
late,  often  at  a  very  advanced  stage  of  the  disease,  as
a  large  lesion,  which  is  hypervascularized  in  the  arterial
phase  in  a  non-dysmorphic  liver  [18,19]  (Fig.  3).
Invasion and pre-treatment assessment
Apart  from  the  speciﬁc  features  of  the  tumor,  the  presence
of  local  or  systemic  invasion  and  extent  of  the  underlying
liver  disease  contribute  to  the  treatment  decision  through
the  BCLC  classiﬁcation  [3].Local invasion
The  most  common  local  invasion  is  vascular.  Vascular  micro-
invasion  is  not  accessible  to  imaging  and  is  proportional  to
a
t
cd late (d) phases; T2 weighted images (e) and diffusion-weighted
he  size  of  the  tumor.  The  presence  of  satellite  nodules
round  a  bulky  tumor  is  a  sign  of  microvascular  invasion
Fig.  4).
The  most  common  vascular  invasion  seen  is  portal.  A
umor  thrombus  may  have  the  same  appearances  as  the
umor,  i.e.  hypervascularized  in  the  arterial  phase  with
ashout  from  the  lesion  in  the  portal  phase.  Vascular  inva-
ion  of  the  portal  trunk  may  appear  as  an  arterio-portal
stula  (Fig.  5)  and  if  appearances  of  an  arterio-portal  ﬁstula
re  seen  in  a cirrhotic  patient  even  if  it  may  be  non-
alignant  in  origin,  the  patient  should  be  investigated  for
epatocellular  carcinoma,  particularly  as  the  tumor  may
e  mostly  endoportal  with  a very  small  parenchymal  mass
nd  is  often  inﬁltratve  and  therefore  more  difﬁcult  to  iden-
ify.
Conversely,  thrombus  associated  with  a hepatocellular
arcinoma  is  not  necessarily  tumor  and  may  be  made  up  of
712  V.  Cartier,  C.  Aubé
Figure 2. Early hepatocellular carcinoma (HCC). Computed tomography after iodine enhancement in the arterial (a), portal (b) and late
(c) phases. Monitoring of severe alcoholic cirrhosis. An 18 mm lesion (arrow) representing a histologically proven hepatocellular carcinoma
(early HCC). The outlines are blurred and arterial phase iodine enhancement is very slight. There is no washout in the portal or late phases.
Figure 3. Hepatocellular carcinoma in a healthy liver. Computed tomography without (a) and then after iodine enhancement in the
arterial (b), portal (c) and late (d) phases. Assessment of abdominal pain. The patient was found to have a 9 cm bulky lesion in the right
lobe of the liver with a necrotic center, which was hypervascularized in the arterial phase, with no washout from the lesion.
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Figure 4. Bulky hepatocellular carcinoma with a satellite nodule on magnetic resonance imaging. T1 weighted images with fat saturation
), po
 arte
ent kwithout (a) and then after gadolinium enhancement in the arterial (b
carcinoma, 9 cm in size, encapsulated and necrotic, enhancing in the
nodule (arrow) under a centimeter in size with the same enhancemﬁbrin,  in  which  case  it  carries  a  different  prognosis.  In  order
to  distinguish  ﬁbrin  from  tumor  thromboses,  an  attempt
should  be  made  to  identify  vascularization  in  the  thrombus,
which  suggests  tumor  invasion.  This  may  be  carried  out  by
c
M
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t
Figure 5. Hepatocellular carcinoma (HCC) with arterio-portal tumor
phases. Viral cirrhosis (c). Hepatocellular carcinoma in the left lobe of 
thrombus. Opaciﬁcation of the portal trunk and its branches from the a
(arrow heads).rtal (c) and late (d) phases. Alcoholic cirrhosis. Bulky hepatocellular
rial phase with washout in the portal and late phases. Small satellite
inetics.ontrast-enhanced  ultrasound  or  contrast-enhanced  CT  or
RI.  If  any  doubt  remains,  a  biopsy  of  the  thrombus  may  be
aken  from  one  of  the  portal  branches  in  order  to  establish
he  type  of  thrombus.
 ﬁstula. Computed tomography in the arterial (a) and portal (b)
the liver with proximal left arterio-portal ﬁstula and portal tumor
rterial phase. Hypodense appearance of the HCC in the late phase
7a
c
e
g
e
d
i
(
a
R
M
n
a
p
c
N
a
I
t
l
p
t
c
a
r
P
A
i
w
(
•
•
d
h
r
S
T
F
r14  
Invasion  of  the  suprahepatic  veins  is  rarer  but  must
lways  be  looked  for.  This  may  extend  to  the  inferior  vena
ava.
Biliary  invasion  is  also  rare,  although  forms  of  the  dis-
ase  are  found  which  result  in  predominantly  endobiliary
rowth.  The  underlying  liver  disease  and  appearances  of  an
ndobiliary  rather  than  inﬁltrative  mass  should  suggest  the
iagnosis  of  HCC  rather  than  cholangiocarcinoma.  A  biopsy
s  required  for  an  unequivocal  diagnosis.
Invasion  of  the  liver  capsule  and  neighboring  structures
particularly  the  abdominal  wall)  should  be  looked,  for
lthough  these  are  uncommon.
emote disease
etastases  occur  mostly  in  the  lungs,  abdominal  and  lymph
odes  and  in  bone  [20].  Caution,  however,  is  required,  when
ssessing  whether  or  not,  particularly  hilar  lymphadeno-
athy,  is  metastatic  as  inﬂammatory  lymphadenopathy  is
ommon  in  viral  liver  disease.
on-malignant aspects of the pre-treatment
ssessment
n  addition  to  clinical  and  laboratory  ﬁndings  which  reﬂect
he  underlying  liver  disease,  the  radiological  features  of  the
iver  disease  should  be  reported.
Hepatic  dysmorphism,  particularly  atrophy,  inﬂuence  the
otential  for  excision.
Portal  hypertension  is  a  major  prognostic  indicator  in  the
reatment  of  HCC.  In  addition  to  clinical  assessment  indi-
ators  (porto-suprahepatic  gradient,  indocyanine  green  test
s
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nd  Fibroscan),  CT  and  esophagogastroscopy  should  be  car-
ied  out  to  look  for  portosystemic  shunts.
ositive diagnosis
s  deﬁned  in  the  recent  EASL  and  EORTC  deﬁnitions,  a  pos-
tive  diagnosis  of  hepatocellular  carcinoma  can  be  made
ithout  histology  deﬁnitions  under  certain  conditions  [6]
Fig.  6).
To  summarize  this  ﬁgure:
a lesion  under  a  centimeter  in  size  should  be  followed  up
at  3  months;
a lesion  over  a  centimeter  in  size  may  be  diagnosed
with  certainty  if  underlying  cirrhosis  is  present  and  imag-
ing  appearances  are  typical  (arterial  hypervascularization
with  washout  from  the  lesion  in  the  portal  and/or  late
phase)  on  CT  and/or  MRI  (if  either  of  these  investigations
is  negative,  the  second  should  be  performed).
Outside  of  these  situations  the  diagnosis  requires  a  nee-
le  biopsy  for  histological  examination.  If  this  is  negative  (no
istological  identiﬁcation  of  the  nodule),  a further  biopsy  is
equired.
tandardized report
he  different  aspects  of  the  diagnosis  described  above
hould  be  included  in  as  standardized  a  report  as  possible
Appendix  A),  which  should  state  the  clinical  ﬁndings  (Child-
ugh  classiﬁcation,  cause  of  the  lesion),  history  of  any  HCC
lready  treated,  the  signs  of  liver  disease  (dysmorphism,
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over  1  cm  in  size  in  a  cirrhotic  liver  is  not  acceptable.
3.  The  subtraction  image  (arterial  —  without  injection)Diagnosis  of  hepatocellular  carcinoma  
portal  hypertension);  a  description  of  the  lesion(s)  sus-
pected  to  be  HCC;  local  and  general  extension;  whether
the  diagnosis  of  HCC  can  be  conﬁrmed  on  imaging  (typical
appearance  according  to  the  guidelines)  or  whether  needle
biopsy  is  needed.
Conclusion
Hepatocellular  carcinoma  occurs  on  a  background  of  chronic
liver  disease  and  should  therefore  be  screened  for  rou-
tinely  by  six-monthly  ultrasound.  An  unequivocal  diagnosis
can  be  made  on  imaging  because  of  the  typical  appear-
ances  as  they  are  deﬁned  in  the  international  guidelines,
although  if  these  typical  appearances  are  not  present,  any
nodule  developing  in  cirrhosis  over  a  centimeter  in  size  must
be  biopsied  to  obtain  an  unequivocal  histological  diagno-
sis.  As  applies  to  any  cancer,  a  local  and  general  staging
assessment  should  be  performed.  In  addition  and  because  of
the  underlying  liver  disease  which  inﬂuences  the  treatment
decision,  information  about  the  liver  disease  such  as  hepatic
dysmorphism  and  portal  hypertension  should  be  included.
The  treatment  decision  is  based  on  the  BCLC  classiﬁcation
(Table  1).
TAKE-HOME  MESSAGES
• Screening  for  HCC  should  be  by  six-monthly
ultrasound.
• Atypical  appearances  (arterial  enhancement  and
portal  and/or  late  phase  washout)  allow  a
noninvasive  diagnosis  of  HCC  in  cirrhosis  to  be
made.
• In  all  other  situations,  a  biopsy  is  required  to  conﬁrm
the  diagnosis.
• The  staging  assessment,  including  imaging,  should
incorporate  an  assessment  of  the  underlying  liver
disease. 4
Table  1  Barcelona  Clinic  Liver  Cancer  (BCLC)  Classiﬁcation.
BCLC  stages  PS  Tumor  features  
Early  HCC
A1  0  Single,  <  5  cm  
A2  0  Single,  <  5  cm  
A3  0  Single,  <  5  cm  
A4  0  3  tumors  <  3  cm  
Intermediate
B  0  Large  multinodular  
Advanced
C  1—2  Vascular  invasion  or  metast
End  stage
D 3—4 Any  
HCC: hepatocellular carcinoma.
A and B stages: all the criteria. C and D stages: one of the criteria.715
linical case
 71-year-old  male  patient  was  being  followed  up  for  viral
irrhosis.  He  was  found  on  a  six-monthly  ultrasound  to  have
 15  mm  hypoechogenic  nodule  in  the  right  lobe  of  the  liver.
A  CT  (Fig.  7)  performed  without  and  then  with  iodine
nhancement  in  the  arterial,  portal  and  late  phases,  con-
rmed  a  non-liquid,  15  mm  hypodense  nodule,  which  did  not
nhance.  MRI  (Fig.  8) with  T1  weighted  images  both  without
a)  and  then  with  gadolinium  enhancement  in  the  arterial
b),  portal  (c)  and  late  (d)  phases  and  T2  weighted  image
e)  were  obtained  and  conﬁrmed  a  hypointense  nodule  in
he  right  lobe  of  the  liver  on  a  T1  weighted  image,  which
id  not  enhance  signiﬁcantly  in  the  arterial  phase  and  which
as  hypointense  in  the  portal  and  late  phases.
uestions
.  Why  can  you  not  make  a  conclusive  diagnosis  of  HCC?
.  What  is  your  practical  approach?
.  Which  image  allows  you  to  conﬁrm  that  there  is  no  arte-
rial  enhancement?
. Do  you  conclude  that  the  diagnosis  is  HCC?
.  What  is  your  practical  approach  then?
.  The  histologist  reported  a  moderately  differentiated
HCC.  What  hypotheses  would  you  offer  to  explain  the
appearances  of  this  HCC?
nswers
.  Because  of  the  lack  of  arterial  enhancement  and  washout
from  the  lesion.
.  Another  investigation  (MRI)  would  be  useful  to  look  for
the  typical  appearances  of  HCC,  allowing  a  positive  non-
invasive  diagnosis  to  be  made.  Simply  monitoring  a  lesion(Fig.  8f).
.  No.  Not  typical  appearances  of  HCC.
Liver  functions
No  portal  hypertension  and  normal  bilirubin
Portal  hypertension  and  normal  bilirubin
Portal  hypertension  and  abnormal  bilirubin
Child-Pugh  A—B
Child-Pugh  A—B
ases  Child-Pugh  A—B
Child-Pugh  C
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Figure 7. Computed tomography without and then with iodine enhancement in the arterial, portal and late phases conﬁrming the presence
of a non-liquid, hypodense 15 mm nodule, not enhancing with contrast.
Diagnosis  of  hepatocellular  carcinoma  717
Figure 8. Magnetic resonance imaging with T1 weighted images without (a) and then after gadolinium enhancement in the arterial (b),
g a h
 port
D
Tportal (c) and late (d) phases and T2 weighted image (e) conﬁrmin
enhancing signiﬁcantly in the arterial phase and hypointense in the
5.  Perform  a  biopsy,  simply  monitoring  the  lesion  over
1  cm  in  size  in  a  cirrhotic  liver  is  not  accept-
able.6.  Probable  tumor  necrosis. cyperintense T1 weighted nodule in the right lobe of the liver not
al and late phases.
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